Phase 4 N=82 Study of Oasis Ultra in Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wounds Closed — 54; 32 percentage of wounds closed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=300 Post-operative Dental Pain Study Comparing Analgesic Efficacy
Post-surgical Dental Pain
Primary: Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours) — 10.60; 5.87; 3.35 Units on a scale — p=0.0004
N/A N=100 Comparison Study of Two Supraglottic Airway Devices Used for Patients Under General Anesthesia
Anesthesia Airway Management
Primary: Measure of the Airway Leak Pressure — 23; 21 cmH2O
Phase 2 N=189 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 42.9…
Phase 3 N=375 Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Precancerous Condition
Primary: Detection of Any Adenoma at the End of the Study — 17; 53; 121; 76 participants
Phase 2 N=51 Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Melanoma
Primary: Determine the Overall Objective Response Rate (CR and PR). — 0; 6; 16; 27 participants
Phase 2 N=27 Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
Sickle Cell Disease
Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC
Phase 2 N=88 A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery
Major Upper or Lower Abdominal Surgery
Primary: SPID-12 — 22.41; 27.56; 2.93 units on a scale — p=<0.001
Phase 2 N=83 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Neoplasms
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 52.9; 53.1 percentage of participants
N/A N=265 Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
HIV Infections
Primary: Number of Patients With Virologic Response (VR) After 36 Months — 44; 30; 46; 40 participants
Phase 4 N=11 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Hepatitis C
Primary: Delta Hepatitis C Viral Load — 15 percent change
N/A N=166 Reduction of Sitting Time: Sedentarism Intervention Trial
Life Style · Physical Activity · Sedentary Behavior
Primary: Change in Objectively Measured Sitting Time From Baseline to 6 Months Follow-up — -0.27; 0.06 Hours per day
Phase 1 N=59 Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects
Healthy
Primary: OZ439 Cmax — 142; 139; 146; 198 ng/mL
Phase 4 N=60 Spinal Anaesthesia With Levobupivacaine 0.5% and Ropivacaine 0.75% for Lower Limb Orthopaedic Surgery
Lower Limb Surgery
Primary: Duration of Analgesia — 309.83; 249.50 minutes
Phase 1 N=12 Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration — 716; 673; 570; 554 ng/mL